Novartis Raises 2026 Core Operating Income Guidance Following Sales Growth
Novartis (NVS) has upgraded its full-year 2026 core operating income guidance to in-line or low-single-digit growth, reversing previous projections of a decline. This positive shift follows a third quarter characterized by 4% net sales growth and a significant 7% reduction in selling, general, and administrative (SG&A) expenses. The company's ability to offset revenue losses from patent expirations with high-performing new launches is central to its long-term strategy. Specifically, management increased peak sales projections for Rhapsido to over $4 billion across combined indications. Novartis aims to leverage these efficiencies and pipeline successes to reach a 40% core operating margin target by 2029.
Tickers: $NVS
Topics: earnings report guidance upgrade operating income pharmaceuticals
Read the full article at Motley Fool
Part of the story Novartis Raises 2026 Core Operating Income Guidance Following Sales Growth (7 articles)